ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY
Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Reports Third Quarter 2025 Financial Results and Provides Business Update
News
Reports Second Quarter 2025 Financial Results and Provides Business Update
FY 2024
Q3
Q2
Q1
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
SEC Staff Correspondence
Submission Upload
Correspondence
Confidential Treatment Order